HELPCybin Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 16470
Ticker: HELP
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-11-10
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: HELP

Detail

Enriched 2026-08-14 20:47

Market cap: $712,197,056.22
Shares outstanding (class): 69,873,924
Shares outstanding (weighted): 61,984,078
SIC: —
Employees: 50
Location: —
Homepage: https://www.helus.com
Description: Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Market cap and share counts drift.

Funds holding this security

4 funds · 4 positions · $8.44M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST	—	$6.77M	0.43%	1,410,815 NS	FIGI
AdvisorShares Psychedelics ETF AdvisorShares Trust	PSIL	$938.9K	4.64%	195,604 NS	FIGI
Royce Smaller-Companies Growth Fund ROYCE FUND	—	$744.0K	0.41%	155,000 NS	FIGI
Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds	—	-$12.0K	-0.00%	-2,500 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERHELP
FIGI_COMPOSITEBBG00MFNRRT4
FIGI_SHARE_CLASSBBG00HZ0NJ24
CIK0001833141
ISINCA23256X4075
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Cybin is a biopharmaceutical company developing psychedelic-based therapies, fitting the biotechnology industry within healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.